Trial Profile
Phase 3 trial of the antiangiogenic agent thalidomide in patients with malignant mesothelioma after first line chemotherapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 Dec 2013
Price :
$35
*
At a glance
- Drugs Thalidomide (Primary) ; Carboplatin; Cisplatin; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Biomarker; Therapeutic Use
- Acronyms NVALT-5
- 04 Jan 2007 New trial record.